First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

被引：0
作者：
Tianhong Li
Patricia LoRusso
Michael L. Maitland
Sai-Hong Ignatius Ou
Erkut Bahceci
Howard A. Ball
Jung Wook Park
Geoffrey Yuen
Anthony Tolcher
机构：
[1] University of California Davis Comprehensive Cancer Center,Division of Hematology/Oncology
[2] Wayne State University,Karmanos Cancer Institute
[3] University of Chicago Medicine,Section of Hematology/Oncology, Committee on Clinical Pharmacology and Pharmacogenomics
[4] University of California Irvine School of Medicine,Chao Family Comprehensive Cancer Center
[5] Astellas Pharma Global Development,undefined
[6] South Texas Accelerated Research Therapies (START) Center for Cancer Care,undefined
[7] Present address: Yale Smilow Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
ASP3026; Neoplasms; ALK inhibitor; Phase I; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
    Murakami, H.
    Kurata, T.
    Onozawa, Y.
    Watanabe, J.
    Ono, A.
    Takahashi, T.
    Yamamoto, N.
    Fujisaka, Y.
    Kiyota, H.
    Hayashi, H.
    Tanaka, K.
    Nakagawa, K.
    Kuroda, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 623 - 630
  • [22] A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
    du Bois, A.
    Huober, J.
    Stopfer, P.
    Pfisterer, J.
    Wimberger, P.
    Loibl, S.
    Reichardt, V. L.
    Harter, P.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 370 - 375
  • [23] A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
    Mehnert, Janice M.
    Edelman, Gerald
    Stein, Mark
    Camisa, Heather
    Lager, Joanne
    Dedieu, Jean-Francois
    Ghuysen, Anne-Frederique
    Sharma, Jyoti
    Liu, Li
    LoRusso, Patricia M.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 36 - 44
  • [24] Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
    Hong, D. S.
    Bauer, T. M.
    Lee, J. J.
    Dowlati, A.
    Brose, M. S.
    Farago, A. F.
    Taylor, M.
    Shaw, A. T.
    Montez, S.
    Meric-Bernstam, F.
    Smith, S.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Cox, M. C.
    Burris, H. A., III
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30 (02) : 325 - 331
  • [25] A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
    Janice M. Mehnert
    Gerald Edelman
    Mark Stein
    Heather Camisa
    Joanne Lager
    Jean-François Dedieu
    Anne-Frédérique Ghuysen
    Jyoti Sharma
    Li Liu
    Patricia M. LoRusso
    Investigational New Drugs, 2018, 36 : 36 - 44
  • [26] A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
    Li, Xiaoyu
    Qiu, Meng
    Wang, ShengJun
    Zhu, Hong
    Feng, Bi
    Zheng, Li
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (03) : 593 - 604
  • [27] Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
    Bauer, Todd M.
    Besse, Benjamin
    Martinez-Marti, Alex
    Trigo, Jose Manuel
    Moreno, Victor
    Garrido, Pilar
    Ferron-Brady, Geraldine
    Wu, Yuehui
    Park, Jennifer
    Collingwood, Therese
    Kruger, Ryan G.
    Mohammad, Helai P.
    Ballas, Marc S.
    Dhar, Arindam
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1828 - 1838
  • [28] A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
    Xiaoyu Li
    Meng Qiu
    ShengJun Wang
    Hong Zhu
    Bi Feng
    Li Zheng
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 593 - 604
  • [29] Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
    Hong, David S.
    Kurzrock, Razelle
    Wheler, Jennifer J.
    Naing, Aung
    Falchook, Gerald S.
    Fu, Siqing
    Kim, Kevin B.
    Davies, Michael A.
    Nguyen, Ly M.
    George, Goldy C.
    Xu, Lucy
    Shumaker, Robert
    Ren, Min
    Mink, Jennifer
    Bedell, Cynthia
    Andresen, Corina
    Sachdev, Pallavi
    O'Brien, James P.
    Nemunaitis, John
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4801 - 4810
  • [30] Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
    Chen, Qiuyan
    Tang, Linquan
    Liu, Na
    Han, Feng
    Guo, Ling
    Guo, Shanshan
    Wang, Jianwei
    Liu, Huai
    Ye, Yanfang
    Zhang, Lu
    Liu, Liting
    Wang, Pan
    Li, Yingqin
    He, Qingmei
    Yang, Xiaoqun
    Tang, Qingnan
    Li, Yang
    Liang, YuJing
    Sun, XueSong
    Xie, Chuanmiao
    Mo, Yunxian
    Guo, Ying
    Sun, Rui
    Mo, Haoyuan
    Cao, Kajia
    Guo, Xiang
    Zeng, Musheng
    Mai, Haiqiang
    Ma, Jun
    CANCER COMMUNICATIONS, 2018, 38
12345